Schmidl, D.; Hommer, N.; Kallab, M.; Schlatter, A.; Nadvornik, C.; Obermayr, F.; Sperl, S.; Daniels, E.J.; Garhöfer, G.
Safety and Tolerability of KIO-101 Eye Drops in Healthy Volunteers and Patients with Ocular Surface Disease—A Phase I Study. Pharmaceutics 2024, 16, 367.
https://doi.org/10.3390/pharmaceutics16030367
AMA Style
Schmidl D, Hommer N, Kallab M, Schlatter A, Nadvornik C, Obermayr F, Sperl S, Daniels EJ, Garhöfer G.
Safety and Tolerability of KIO-101 Eye Drops in Healthy Volunteers and Patients with Ocular Surface Disease—A Phase I Study. Pharmaceutics. 2024; 16(3):367.
https://doi.org/10.3390/pharmaceutics16030367
Chicago/Turabian Style
Schmidl, Doreen, Nikolaus Hommer, Martin Kallab, Andreas Schlatter, Clemens Nadvornik, Franz Obermayr, Stefan Sperl, Eric J. Daniels, and Gerhard Garhöfer.
2024. "Safety and Tolerability of KIO-101 Eye Drops in Healthy Volunteers and Patients with Ocular Surface Disease—A Phase I Study" Pharmaceutics 16, no. 3: 367.
https://doi.org/10.3390/pharmaceutics16030367
APA Style
Schmidl, D., Hommer, N., Kallab, M., Schlatter, A., Nadvornik, C., Obermayr, F., Sperl, S., Daniels, E. J., & Garhöfer, G.
(2024). Safety and Tolerability of KIO-101 Eye Drops in Healthy Volunteers and Patients with Ocular Surface Disease—A Phase I Study. Pharmaceutics, 16(3), 367.
https://doi.org/10.3390/pharmaceutics16030367
